- Home
- DSL vs KNSA Comparison
DSL vs KNSA Comparison
Compare DSL & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- KNSA
- Stock Information
- Founded
- DSL 2013
- KNSA 2015
- Country
- DSL United States
- KNSA United Kingdom
- Employees
- DSL N/A
- KNSA N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- DSL Finance
- KNSA Health Care
- Exchange
- DSL Nasdaq
- KNSA Nasdaq
- Market Cap
- DSL 1.3B
- KNSA 1.5B
- IPO Year
- DSL N/A
- KNSA 2018
- Fundamental
- Price
- DSL $11.82
- KNSA $20.76
- Analyst Decision
- DSL
- KNSA Strong Buy
- Analyst Count
- DSL 0
- KNSA 6
- Target Price
- DSL N/A
- KNSA $37.17
- AVG Volume (30 Days)
- DSL 719.5K
- KNSA 661.6K
- Earning Date
- DSL 01-01-0001
- KNSA 05-06-2025
- Dividend Yield
- DSL 11.32%
- KNSA N/A
- EPS Growth
- DSL N/A
- KNSA N/A
- EPS
- DSL N/A
- KNSA N/A
- Revenue
- DSL N/A
- KNSA $423,239,000.00
- Revenue This Year
- DSL N/A
- KNSA $37.21
- Revenue Next Year
- DSL N/A
- KNSA $2.58
- P/E Ratio
- DSL N/A
- KNSA N/A
- Revenue Growth
- DSL N/A
- KNSA 56.60
- 52 Week Low
- DSL $10.58
- KNSA $17.04
- 52 Week High
- DSL $13.24
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- DSL 43.87
- KNSA 50.01
- Support Level
- DSL $11.44
- KNSA $19.62
- Resistance Level
- DSL $11.86
- KNSA $20.89
- Average True Range (ATR)
- DSL 0.34
- KNSA 1.17
- MACD
- DSL 0.02
- KNSA -0.02
- Stochastic Oscillator
- DSL 65.88
- KNSA 74.36
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.